GlassScriptPhysician profile
Abram T Seavers
NPI 1154314391
$3,560.43
in general payments reported to CMS, 2019-2025
22 companies · $817 in 2025
The $817 reported for 2025 was more than what 76% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $164 · 2021: $272 · 2022: $790 · 2023: $439 · 2024: $819 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,074.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $469.52 | 2024-2025 | Krystexxa |
| Convatec INC. | $414.07 | 2023-2024 | |
| Horizon Therapeutics Plc | $410.36 | 2020-2023 | Krystexxa |
| Organogenesis INC. | $270.88 | 2022-2025 | Puraply, Simplimax |
| Medtronic, INC. | $257.80 | 2024 | Intellis Adaptivestim |
| Paratek Pharmaceuticals, INC. | $252.25 | 2022-2025 | Nuzyra |
| Kerecis Limited | $234.37 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Stryker Corporation | $206.35 | 2019-2020 | |
| Triad Life Sciences INC. | $205.53 | 2022 | |
| Ani Pharmaceuticals, INC. | $185.41 | 2024-2025 | Purified Cortrophin Gel |
| Heron Therapeutics, INC. | $125.00 | 2021 | |
| Ossio INC | $120.00 | 2022 | |
| Melinta Therapeutics, LLC | $83.14 | 2019 | |
| Aroa Biosurgery Incorporated | $72.23 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $55.61 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $43.68 | 2022-2023 | Senza |
| Gramercy Extremity Orthopedics LLC | $36.90 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $36.25 | 2019 | |
| Smith+Nephew, INC. | $29.14 | 2022-2025 | Stravix |
| Abbvie INC. | $19.37 | 2025 | |
| Paragon 28, INC. | $16.30 | 2024 | Bun-Yo-Matic |
| Solventum Corporation | $16.27 | 2025 | Activ.A.C. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abram Seavers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.